Health Tech Daily Brief - October 6, 2026

Government backs recommendations of NHS doctors-led AI Commission

The UAE is becoming a test bed for medical AI. But the real test begins after the pilot

Algorae Pharmaceuticals Ltd (ASX:1AI): Commercial Expansion, AI Drug Discovery and FY26 Developments

Telemedicine After 2020: How India’s Regulatory Framework Shaped Digital Care

e-Sanjeevani: National Telemedicine Service crosses 500 mn tele consultations | India News

eSanjeevani Crosses 50 Crore Consultations, Expands Specialist Care Through AIIMS

ARPA-H awards more than $100M to biosensor development projects

Happy Health Becomes First Company to Receive FDA Clearance for Cuffless, Calibrationless Blood Pressure Measurement

Responding more frequently to MiniMed Smart MDI alerts linked to better glucose outcomes for people with diabetes

Oracle medical data breach affected nearly 20 million people

Arcadia Unveils Ascent, CareJourney, and LifeScience to Operationalize Agentic Population Health

Investing in Community Health: A New Model for Safety-Net Healthcare Innovation

Launched last week, Facktor Ventures, an early-stage venture fund is taking a new approach to healthcare investing: they’re structured so that the organizations delivering care on the ground collectively become majority owners of the fund as limited partners. The post Investing in Community Health: A New Model for Safety-Net Healthcare Innovation appeared first on MedCity News.

Should traditional Medicare emulate Medicare Advantage by capping patients’ out-of-pocket maximums?

Nurses Have Until October 19 to Weigh In on the FDA’s Generative AI Device Framework

CMS Finalizes Rules to Improve Healthcare Price and Coverage Transparency

Arlington maritime startup raises $140M in Series B funding

Defense Startups Draw Record $40.8 Billion in Funding

Shionogi Adds to Its Rare Disease Strategy With $2B IntraBio Acquisition

Shionogi’s IntraBio acquisition brings Aqneursa, a drug approved for treating two rare neurological disorders and the potential to expand to additional indications, both rare and common. It’s Shionogi’s second big rare disease move this year, following the acquisition of global rights to an amyotrophic lateral sclerosis drug from Tanabe Pharma. The post Shionogi Adds to Its Rare Disease S…

FDA Clearance Positions Click Therapeutics’ Motivista for Commercial Rollout

FDA Clears Motivista (CT-155), the First Authorized Treatment for Negative Schizophrenia Symptoms

Meet Motivista: Click Therapeutics debuts first-of-its-kind schizophrenia digital therapeutic

A reckoning on social media addiction came late for many kids. Will AI safety be different?